Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
Quick Facts
What This Study Found
Semaglutide significantly reduces weight and shows hepatoprotective and neuroprotective effects.
Key Numbers
How They Did This
The study is a narrative review summarizing findings from various clinical and pre-clinical trials.
Why This Research Matters
Understanding semaglutide's broader therapeutic potential could lead to new treatments for obesity and neurodegenerative diseases. Its approval for obesity management highlights its clinical relevance.
What This Study Doesn't Tell Us
The review is based on existing studies and does not present new experimental data.
Trust & Context
- Original Title:
- Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
- Published In:
- Pharmaceutical research, 39(6), 1233-1248 (2022)
- Database ID:
- RPEP-06344
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06344APA
Mahapatra, Manoj K; Karuppasamy, Muthukumar; Sahoo, Biswa M. (2022). Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.. Pharmaceutical research, 39(6), 1233-1248. https://doi.org/10.1007/s11095-022-03302-1
MLA
Mahapatra, Manoj K, et al. "Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.." Pharmaceutical research, 2022. https://doi.org/10.1007/s11095-022-03302-1
RethinkPeptides
RethinkPeptides Research Database. "Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor..." RPEP-06344. Retrieved from https://rethinkpeptides.com/research/mahapatra-2022-therapeutic-potential-of-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.